Tralokinumab

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis[1][2].

Product Specifications

CAS Number

[1044515-88-9]

Product Name Alternative

CAT354

UNSPSC

12352203

Target

Apoptosis; Cadherin; Caspase; Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Cytoskeleton; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tralokinumab.html

Purity

99.12

Solubility

H2O

Smiles

[Tralokinumab]

Molecular Weight

(144.14 kDa)

References & Citations

[1]A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) . Br J Dermatol. 2021 Mar;184 (3) :437-449.|[2]Murray LA, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014 May;50 (5) :985-94.